Within the cataract removal procedures which take place a variety of complications may occur including;

chronic inflammation inside the eye
retinal detachment
infection

Rehabilitation
There are several medications which need to be consumed in order to treat phacolytic glaucoma. The medicines induced ensure the management of glaucoma and reduce inflammation. These medications consist of: Aqueous suppressants, anti-inflammatory drugs, hyper-osmotic agents, cycloplegics, anti-glaucoma medications. Medical therapy, however, is only a temporary treatment until cataract surgery can take place.The use of an eyepatch for a certain amount of time, as well as a contact lens to protect the eye which dissolves releasing antibiotics, must be incorporated in the rehabilitation process to reduce the risk of infection of the eye and to allow for an effective healing process. Additionally, the patient must consistently visit the specialist in order to ensure a successful removal of phacolytic glaucoma. There may be a need for medical therapies which treat arising issues for the eye such as inflammation. These medical therapy procedures for phacolysis consist of controlling the intraocular pressure which may include the use of topical steroids in order to decrease inflammation in the eye, and mydriatics in order to prevent the formation of synechiae. Medication
It is found that with most cases, of phacolytic glaucoma post surgery patients are not exposed to many further obstacles in the healing process which therefore avoids the need for medication. Although, it is mostly encouraged that patients take antiglaucoma medication in order to deter the possibility of glaucoma and inflammation implicating the eye.
Diflorasone diacetate is a topical steroid that comes in the form of a cream. It is manufactured by E. Fougera & Co. and is used as an anti-inflammatory and anti-itching agent, like other topical corticosteroids. It is prescribed for psoriasis and atopic dermatitis, among other conditions. With respect to potency, it is regarded as a Class I corticosteroid [of classes I – VII] in the United States.No long-term animal studies have been done to determine whether diflorasone diacetate could have carcinogenic properties.Little data is available regarding whether diflorasone diacetate would be present in great enough quantities to cause harm to an infant. References
External links
"Diflorasone diacetate". Drug Information Portal. U.S. National Library of Medicine.